Genelux (GNLX) Q4 2025 earnings summary

Executive summary

• Topline data from the Phase 3 OnPrime/GOG-3076 ovarian cancer trial of Olvi-Vec expected in 2H26.

• Interim data in lung cancer showed partial responses in relapsed SCLC and anti-tumor activity in NSCLC; further updates expected in 2026.

• Jason Litten, M.D., appointed Chief Medical Officer to lead clinical development.

• Advancing manufacturing and operational capabilities for potential commercial readiness.

Financial highlights

• Cash, cash equivalents, marketable securities, and restricted cash totaled $14.6M as of Dec 31, 2025; pro forma $33.1M after January 2026 offering.

• Net loss was $32.1M ($0.86/share) for 2025, compared to $29.9M ($0.95/share) in 2024.

• R&D expenses increased to $19.9M in 2025 from $19.0M in 2024, mainly due to higher clinical trial costs.

• G&A expenses rose to $13.4M in 2025 from $12.7M in 2024, driven by higher compensation and headcount.

Outlook and guidance

• Cash runway expected to fund operations into 1Q27 based on current plans.

• Additional dose-finding updates from SCLC and NSCLC trials anticipated throughout 2026.

• Focused on optimizing systemic dosing regimen for future registrational development.